TP Therapeutics is a clinical-stage precision oncology company developing Repotrectinib (TPX-0005), an oral small-molecule inhibitor targeting ALK, ROS1 and TRK family kinases. Repotrectinib has shown potency against wild-type and mutated kinases, including solvent front, gatekeeper and compound mutations that confer resistance to current inhibitors. The asset is being evaluated in a first-in-human Phase 1/2 TRIDENT-1 study (NCT03093116) and the company plans to advance it into a Phase 2 potential registration study in early 2019 for ROS1-positive NSCLC and NTRK-positive solid tumors. That planned study will enroll patients who have developed resistance to prior tyrosine kinase inhibitors as well as TKI treatment‑naïve patients. TP Therapeutics will use proceeds from the completed financing to fund the Phase 2 study and further develop its internally discovered pipeline. Founded in October 2013, the company has reported encouraging interim Phase 1 data presented at the World Conference on Lung Cancer. TP Therapeutics is a clinical-stage, structure-based drug design company founded in October 2013 by Dr. J. Jean Cui. The company's lead program, TPX-0005, is in clinical development (TRIDENT-1, NCT03093116) and targets naïve and resistant patients with ALK, ROS1, or NTRK abnormalities. TPX-0005 is designed to comprehensively address acquired resistance mutations as well as bypass and EMT mechanisms, and the company is exploring its potential in combination therapies to address resistance in other targets such as EGFR. Proceeds from the recent financing will fund continued development of TPX-0005 and the advancement of several pre-clinical pipeline projects. TP Therapeutics focuses on designing novel chemical identities for established oncogene drivers, newly identified disease-driven targets, and targets regulating the tumor microenvironment and tumor immunity. The company operates from San Diego and lists the TRIDENT-1 clinical trial for TPX-0005.

Total raised

$125M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Oct 2018